Literature DB >> 16985640

Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

Stephen J Freedland, Jean B Dekernion.   

Abstract

The potential benefits of a lymph node dissection (LND) include more accurate staging, decreased local recurrence rates, and improved survival. However, only limited data support the potential benefits of routine, extensive LND for renal cell carcinoma (RCC). Because of lack of data, no clear practice standard has been established about whether to perform LND and, if so, to what extent. The value of LND for RCC is only relevant if the pattern of lymphatic spread is predictable, which it is not. However, although little evidence supports the value of LND for RCC, it is probable that an occasional patient will have very early metastasis confined to the area of the primary and secondary major lymphatic flow medially and perhaps will benefit therapeutically. In this case, a limited LND is supportable. No information currently available strongly supports the value of a more extensive and potentially more morbid LND for either staging or therapeutic value. Extensive investigation is necessary in order to establish LND as a standard component of RCC surgery.

Entities:  

Year:  2003        PMID: 16985640      PMCID: PMC1473014     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  30 in total

1.  Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Authors:  J R Vasselli; J C Yang; W M Linehan; D E White; S A Rosenberg; M M Walther
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

2.  Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group.

Authors:  S Naito; J Kumazawa; T Omoto; A Iguchi; K Sagiyama; Y Osada; Y Hiratsuka
Journal:  Int J Urol       Date:  1997-01       Impact factor: 3.369

3.  Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.

Authors:  G Pizzocaro; L Piva; M Colavita; S Ferri; R Artusi; P Boracchi; G Parmiani; E Marubini
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy.

Authors:  W Schafhauser; A Ebert; J Brod; S Petsch; K M Schrott
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

5.  Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system.

Authors:  A Belldegrun; K H Tsui; J B deKernion; R B Smith
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery?

Authors:  A Minervini; L Lilas; G Morelli; C Traversi; S Battaglia; R Cristofani; R Minervini
Journal:  BJU Int       Date:  2001-08       Impact factor: 5.588

Review 7.  Nephron-sparing surgery for renal cell carcinoma.

Authors:  Andrew C Novick
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

8.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  The number of lymph nodes examined and staging accuracy in renal cell carcinoma.

Authors:  C Terrone; S Guercio; S De Luca; M Poggio; E Castelli; C Scoffone; R Tarabuzzi; R M Scarpa; D Fontana; S Rocca Rossetti
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

10.  The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.

Authors:  John F Ward; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

View more
  9 in total

Review 1.  Applications of nanoparticles in the detection and treatment of kidney diseases.

Authors:  Chris Brede; Vinod Labhasetwar
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

Review 2.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

3.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study.

Authors:  Axel Bex; Lenka Vermeeren; Geraldine de Windt; Warner Prevoo; Simon Horenblas; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-29       Impact factor: 9.236

4.  Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients.

Authors:  A Bex; L Vermeeren; W Meinhardt; W Prevoo; S Horenblas; R A Valdés Olmos
Journal:  World J Urol       Date:  2010-11-25       Impact factor: 4.226

Review 5.  The role of lymph node dissection in renal cell carcinoma.

Authors:  Brian F Chapin; Scott E Delacroix; Christopher G Wood
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

6.  The current role of lymph node dissection in the management of renal cell carcinoma.

Authors:  Joseph Edmund Jamal; Thomas William Jarrett
Journal:  Int J Surg Oncol       Date:  2011-06-07

7.  Technical challenges of lymphadenectomy in renal carcinoma performed with a 3D laparoscopic approach at a low pressure pneumoperitoneum due to associated pulmonary pathology - case report.

Authors:  Cristina E Bujoreanu; Yarden Dor; Bogdan Petrut
Journal:  Med Pharm Rep       Date:  2022-07-26

Review 8.  Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma.

Authors:  Axel Bex
Journal:  EJC Suppl       Date:  2013-09

Review 9.  Sentinel lymph node imaging in urologic oncology.

Authors:  Sherif Mehralivand; Henk van der Poel; Alexander Winter; Peter L Choyke; Peter A Pinto; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2018-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.